Kerstin Schütz is an experienced executive and non-executive director with a unique skill set. She has a proven record in technology commercialisation, stakeholder engagement and partnering with industries and universities at a global level. 

Well practiced in research, global and start-up businesses as well as government funding programs, she has deep expertise in the biotech, pharma and agtech sector. Kerstin is a strong connector and passionate about the commercialisation of new technologies that benefit society. With an entrepreneurial spirit, she has mentored multiple start-ups through Strandnberg, incubators and government grant programs like Accelerating Commercialisation. 

Her experience includes working globally with Pfizer and global contract development and manufacturing organisation Vetter Pharma, and senior roles in biotech. This includes setting up the drug discovery group at Bionomics, which has led to a phase 2 asset. Her focus is on strategic collaborations and connections, critical in the translation of intellectual property. She believes in paying it forward by sharing knowledge and networks. 

Kerstin holds a PhD in Biophysics, a Masters in Business Administration from Melbourne Business School and is a graduate of the Australian Institute of Company Directors. Her experience includes board and advisory positions, and she is a member of Walter and Eliza Hall Institute of Medical Research 66ten Investment Review Committee. She also participates in investment review panels for the South Australian Government.